Lataa...
Potent antitumour of the mTORC1/2 dual inhibitor AZD2014 in docetaxel‐sensitive and docetaxel‐resistant castration‐resistant prostate cancer cells
Recent studies indicate mammalian target of rapamycin (mTOR) may play an important role in PCa progression and drug resistance. Here, we investigated the effects of a novel mTORC1/C2 dual inhibitor, AZD2014, on naive and docetaxel (Doc)‐pre‐treated castration‐resistant PCa (CRPC) cells and explored...
Tallennettuna:
| Julkaisussa: | J Cell Mol Med |
|---|---|
| Päätekijät: | , , , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
John Wiley and Sons Inc.
2021
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7933970/ https://ncbi.nlm.nih.gov/pubmed/33507584 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jcmm.16155 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|